Gansu Cancer Hospital
Gansu Cancer Hospital
Lanzhou, Gansu, China6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC | Advanced Extrapulmonary Neuroendocrine Carcinoma | Not yet recruiting | Phase 3 | 2026-09-01 | NCT07720193 | |
| TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer | HER2-positive Advanced Breast Cancer | Recruiting | Phase 3 | 2026-06-03 | NCT07047365 | |
| Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-04-01 | NCT06768931 | |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer | Carcinoma, Medullary, Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, medullary thyroid gland carcinoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2026-03-19 | NCT04211337 | |
| A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced | Gynecological Tumors | Recruiting | Phase 2 | 2025-07-18 | NCT06798207 | |
| Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | Carcinoma, Medullary, Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, medullary thyroid gland carcinoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 4 | 2023-07-25 | NCT05830500 |